Use of protease inhibitors for the prevention of COVID-19.
作者信息
Sagawa Tomoya, Inoue Ken-Ichiro, Takano Hirohisa
机构信息
Department of Environmental Engineering, Graduate School of Engineering, Kyoto University, Kyoto, Japan; Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
School of Nursing, University of Shizuoka, Shizuoka, Japan.
出版信息
Prev Med. 2020 Dec;141:106280. doi: 10.1016/j.ypmed.2020.106280. Epub 2020 Oct 6.
Abstract
摘要
相似文献
1
Use of protease inhibitors for the prevention of COVID-19.使用蛋白酶抑制剂预防新型冠状病毒肺炎。
Prev Med. 2020 Dec;141:106280. doi: 10.1016/j.ypmed.2020.106280. Epub 2020 Oct 6.
2
Pre-exposure prophylaxis during the SARS-CoV-2 pandemic: can PrEP prevent COVID-19-related symptoms?SARS-CoV-2 大流行期间的暴露前预防：PrEP 能否预防 COVID-19 相关症状？
Epidemiol Infect. 2020 Sep 28;148:e231. doi: 10.1017/S0950268820002253.
3
[SARS-CoV-2 protease: an excellent target to develop drugs against COVID-19].[严重急性呼吸综合征冠状病毒2蛋白酶：开发抗2019冠状病毒病药物的理想靶点]
Med Sci (Paris). 2020 Jun-Jul;36(6-7):555-558. doi: 10.1051/medsci/2020106. Epub 2020 Jun 19.
4
Failure of hydroxychloroquine pre-exposure prophylaxis in COVID-19 infection? A case report.羟氯喹预处理预防新型冠状病毒肺炎感染失败？一例病例报告。
J Antimicrob Chemother. 2020 Sep 1;75(9):2706-2707. doi: 10.1093/jac/dkaa213.
5
Impact of Victoria's Stage 3 lockdown on COVID-19 case numbers.维多利亚州三级封锁对新冠病毒病例数的影响。
Med J Aust. 2020 Dec;213(11):494-496.e1. doi: 10.5694/mja2.50872. Epub 2020 Nov 23.
6
Research on Drugs and Vaccines for COVID-19 Should Be Conducted and Published With Caution.关于新冠病毒的药物和疫苗研究应谨慎开展与发表。
J Epidemiol. 2020 Dec 5;30(12):574-575. doi: 10.2188/jea.JE20200408. Epub 2020 Oct 30.
7
COVID-19, health inequities, and methodology's mission.新冠疫情、健康不平等与方法论的使命。
J Clin Epidemiol. 2020 Dec;128:A6-A8. doi: 10.1016/j.jclinepi.2020.10.021.
8
COVID-19 and improved prevention of hospital-acquired infection.新型冠状病毒肺炎与医院获得性感染预防的改善
Br J Anaesth. 2020 Sep;125(3):e318-e319. doi: 10.1016/j.bja.2020.05.037. Epub 2020 May 31.
9
Status of vaccine development for COVID-19.2019冠状病毒病疫苗的研发现状。
Br J Community Nurs. 2020 Dec 2;25(12):620-621. doi: 10.12968/bjcn.2020.25.12.620.
10
Pandemic control: getting to the heart of unintended consequences.疫情防控：深入探讨意外后果的核心
N Z Med J. 2020 Aug 21;133(1520):153-156.
引用本文的文献
1
Highlights on molecular targets in the management of COVID-19: Possible role of pharmacogenomics.新型冠状病毒肺炎治疗的分子靶点概述：药物基因组学的可能作用。
J Int Med Res. 2023 Jan;51(1):3000605231153764. doi: 10.1177/03000605231153764.
2
A novel property of hexokinase inhibition by Favipiravir and proposed advantages over Molnupiravir and 2 Deoxy D glucose in treating COVID-19.法匹拉韦对己糖激酶的抑制作用具有新颖性，与莫努匹韦和 2-脱氧-D-葡萄糖相比，在治疗 COVID-19 方面具有潜在优势。
Biotechnol Lett. 2022 Jul;44(7):831-843. doi: 10.1007/s10529-022-03259-6. Epub 2022 May 24.
3
Influenza A Virus Uses PSMA2 for Downregulation of the NRF2-Mediated Oxidative Stress Response.甲型流感病毒利用 PSMA2 下调 NRF2 介导的氧化应激反应。
J Virol. 2022 Mar 9;96(5):e0199021. doi: 10.1128/jvi.01990-21. Epub 2022 Jan 12.
4
Antiviral Immunity in SARS-CoV-2 Infection: From Protective to Deleterious Responses.新冠病毒感染中的抗病毒免疫：从保护性反应到有害反应
Microorganisms. 2021 Dec 13;9(12):2578. doi: 10.3390/microorganisms9122578.
5
Serine protease inhibitors could be of benefit in the treatment of COVID-19 disease.丝氨酸蛋白酶抑制剂可能对治疗新冠肺炎有益。
Ther Adv Infect Dis. 2021 Jul 13;8:20499361211032048. doi: 10.1177/20499361211032048. eCollection 2021 Jan-Dec.
6
Role of Iron Chelation and Protease Inhibition of Natural Products on COVID-19 Infection.天然产物的铁螯合和蛋白酶抑制作用对新型冠状病毒肺炎感染的影响
J Clin Med. 2021 May 25;10(11):2306. doi: 10.3390/jcm10112306.
本文引用的文献
1
Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial.氨溴索对新型冠状病毒肺炎患者临床结局及死亡率的影响：一项随机临床试验。
Bioimpacts. 2020;10(4):209-215. doi: 10.34172/bi.2020.27. Epub 2020 Jul 19.
2
Preventing the clinical manifestations and disease progression of coronavirus disease using clinically proven protease inhibitors.使用经临床验证的蛋白酶抑制剂预防冠状病毒病的临床表现和疾病进展。
Crit Care. 2020 Aug 18;24(1):511. doi: 10.1186/s13054-020-03235-4.
3
Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series.甲磺酸那法莫司他联合法匹拉韦治疗新型冠状病毒肺炎危重症患者：病例系列
Crit Care. 2020 Jul 3;24(1):392. doi: 10.1186/s13054-020-03078-z.
4
5
Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans.非裔美国人 COVID-19 患者的肺部和心脏病理学：来自新奥尔良的尸检系列。
Lancet Respir Med. 2020 Jul;8(7):681-686. doi: 10.1016/S2213-2600(20)30243-5. Epub 2020 May 27.
6
Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection.将黏液溶解型止咳药及跨膜丝氨酸蛋白酶2（TMPRSS2）蛋白酶抑制剂溴己新重新用于预防和治疗新型冠状病毒肺炎（SARS-CoV-2）感染。
Pharmacol Res. 2020 Jul;157:104837. doi: 10.1016/j.phrs.2020.104837. Epub 2020 Apr 22.
7
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）进入细胞依赖于 ACE2 和 TMPRSS2，可被一种临床验证的蛋白酶抑制剂所阻断。
Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.
8
The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis.雄激素调节的蛋白酶TMPRSS2激活了一个涉及肿瘤微环境成分的蛋白水解级联反应，并促进前列腺癌转移。
Cancer Discov. 2014 Nov;4(11):1310-25. doi: 10.1158/2159-8290.CD-13-1010. Epub 2014 Aug 13.
Zotero 插件